Z1BH34 Stock Overview Operates as a medical technology company worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Zimmer Biomet Holdings, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Zimmer Biomet Holdings Historical stock prices Current Share Price US$148.08 52 Week High US$171.80 52 Week Low US$146.40 Beta 1.02 1 Month Change 0% 3 Month Change 0.67% 1 Year Change n/a 3 Year Change -18.14% 5 Year Change n/a Change since IPO -5.02%
Recent News & Updates
Zimmer Biomet Holdings, Inc. Announces Quarterly Cash Dividend for Fourth Quarter of 2024, Payable on or About January 31, 2025 Dec 18
Zimmer Biomet Holdings, Inc. Receives FDA Clearance for OsseoFit Stemless Shoulder System for Total Shoulder Replacement Dec 14
Zimmer Biomet Receives FDA Clearance for Persona SoluTion PPS Femur Dec 04
Zimmer Biomet Holdings, Inc. Receives FDA Approval for Oxford Cementless Partial Knee, Only Cementless Partial Knee Replacement Implant in the U.S Nov 26
Zimmer Biomet Holdings, Inc. Appoints Arnold Schwarzenegger as Chief Movement Officer Nov 13
Zimmer Biomet Holdings, Inc. Updates Financial Guidance for the Ending December 31, 2024 Nov 02 See more updates
Zimmer Biomet Holdings, Inc. Announces Quarterly Cash Dividend for Fourth Quarter of 2024, Payable on or About January 31, 2025 Dec 18
Zimmer Biomet Holdings, Inc. Receives FDA Clearance for OsseoFit Stemless Shoulder System for Total Shoulder Replacement Dec 14
Zimmer Biomet Receives FDA Clearance for Persona SoluTion PPS Femur Dec 04
Zimmer Biomet Holdings, Inc. Receives FDA Approval for Oxford Cementless Partial Knee, Only Cementless Partial Knee Replacement Implant in the U.S Nov 26
Zimmer Biomet Holdings, Inc. Appoints Arnold Schwarzenegger as Chief Movement Officer Nov 13
Zimmer Biomet Holdings, Inc. Updates Financial Guidance for the Ending December 31, 2024 Nov 02
Zimmer Biomet to Debut New Z1™ Femoral Hip System and Clinical Data on G7® Acetabular System at 2024 AAHKS Annual Meeting Oct 28
Zimmer Biomet Holdings, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 09
Zimmer Biomet Holdings, Inc. Appoints David Demartino as Senior Vice President, Investor Relations Sep 05
Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2024, Payable on or About October 31, 2024 Aug 30 Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2024 Zimmer Biomet Holdings, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 09
Zimmer Biomet Holdings, Inc. Appoints Devdatt Kurdikar to its Board of Directors Jun 20 Zimmer Biomet Holdings, Inc. (NYSE:ZBH) announces an Equity Buyback for $2,000 million worth of its shares. May 30
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2024, Payable on or About July 31, 2024 May 14
Zimmer Biomet Holdings, Inc. Reiterates Financial Guidance for Current Full-Year 2024 May 03
Zimmer Biomet Holdings, Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 04
Zimmer Biomet Holdings, Inc., Annual General Meeting, May 10, 2024 Mar 28
Zimmer Biomet Holdings, Inc. Announces U.S. Food and Drug Administration (FDA) 510(K) Clearance of the Rosa® Shoulder System for Robotic-Assisted Shoulder Replacement Surgery Feb 23
Zimmer Biomet Holdings, Inc. Announces Quarterly Cash Dividend for the First Quarter of 2024, Payable on or About April 30, 2024 Feb 21
Zimmer Biomet Holdings, Inc. Showcases Latest Innovations Across Comprehensive Portfolio at AAOS 2024 Annual Meeting Feb 12
Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Feb 08
Zimmer Biomet Holdings, Inc. to Report Q4, 2023 Results on Feb 08, 2024 Jan 17
Zimmer Biomet Holdings, Inc. Announces Appointment of Louis A. Shapiro to Board of Directors Jan 05
Zimmer Biomet Holdings, Inc. Approves Cash Dividend for the Fourth Quarter of 2023, Payable on or About January 31, 2024 Dec 14
Zimmer Biomet Holdings, Inc. Updates Revenue Guidance for the Year Ending December 31, 2023 Nov 08
Zimmer Biomet Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 11
Zimmer Biomet Holdings, Inc. Announces Quarterly Dividend for Third Quarter of 2023, Payable on or about October 31, 2023 Aug 26 Zimmer Biomet Holdings, Inc. Announces CEO Changes
Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year 2023 Aug 02
Zimmer Biomet Holdings, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 06
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2023, Payable on July 31, 2023 May 16 Zimmer Biomet Holdings, Inc. Reports Unaudited Impairment Charges for the Fourth Quarter Ended December 31, 2022
Zimmer Biomet Holdings, Inc. to Report Q4, 2022 Results on Feb 03, 2023 Jan 07
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) entered into a definitive agreement to acquire Embody, Inc. for approximately $300 million. Jan 06
Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2022, Payable on or About January 31, 2023 Dec 16
Zimmer Biomet Holdings, Inc. Expands Persona(R) Knee System Portfolio with FDA Clearance of Persona(R) Osseoti(R) Keel Tibia for Cementless Knee Replacement Nov 22
Zimmer Biomet Holdings, Inc. Announces One-Year Data from mymobility® Clinical Study at 2022 AAHKS Annual Meeting Nov 06
Zimmer Biomet Holdings, Inc. Updates Financial Guidance for the Year Ending December 31, 2022 Nov 03
Zimmer Biomet Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 06
Zimmer Biomet Holdings, Inc. Receives FDA Clearance for Identity(TM) Shoulder System for Shoulder Replacement Sep 21
Zimmer Biomet Holdings, Inc Approves Quarterly Cash Dividend, Payable on or About October 31, 2022 Aug 27
Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2022 Aug 03
Zimmer Biomet Holdings, Inc. to Report Q2, 2022 Results on Aug 02, 2022 Jul 06
Zimmer Biomet Holdings, Inc. Appoints Keri P. Mattox as Chief Communications and Administration Officer May 27 Zimmer Biomet Holdings, Inc. Approves Quarterly Dividend for Second Quarter of 2022, Payable on or About July 29, 2022
Zimmer Biomet Holdings, Inc. Debuts First-Of-Its-Kind Artificial Intelligence Capabilities for Omni™ Suite Intelligent Operating Room May 12
Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2022 May 04
Extremity Medical, LLC Files Patent Infringement Lawsuit Against Nextremity Solutions, Zimmer Biomet Holdings, Inc. and Zimmer, Inc Apr 07
Zimmer Biomet Holdings, Inc. to Report Q1, 2022 Results on May 03, 2022 Apr 06 Zimmer Biomet Holdings, Inc., Annual General Meeting, May 16, 2022
Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2022 Feb 08
Zimmer Biomet Holdings, Inc. Announces New Data Supporting Clinical Benefits of Mymobility® with Apple Watch® At AAOS 2021 Sep 01
Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2021 Aug 05
Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Year Ending December 31, 2021 May 05
Zimmer Biomet Holdings, Inc. Announces Management Changes Mar 21
Zimmer Biomet Holdings, Inc. Approves Quarterly Cash Dividend for the First Quarter of 2021, Payable on or About April 30, 2021 Mar 12 Zimmer Biomet Holdings, Inc. Announces Board Changes
Zimmer Biomet Holdings, Inc Appoints Vafa Jamali as CEO of 'NewCo' Feb 18
Zimmer Biomet Holdings, Inc. Appoints Ellison (Ellie) M. Humphrey as Chief Transformation Officer Jan 20
Zimmer Biomet Holdings, Inc. to Report Q4, 2020 Results on Feb 05, 2021 Jan 09
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) acquired A&E Medical Corporation from Vance Street Management LLC and others for approximately $250 million. Dec 02
Zimmer Biomet Holdings, Inc. Announces Preliminary Results from mymobility® Clinical Study at 2020 AAHKS Annual Meeting Nov 06
Zimmer Biomet Holdings, Inc. to Report Q3, 2020 Results on Nov 06, 2020 Oct 07
Zimmer Biomet Holdings, Inc. to Report Q3, 2019 Results on Nov 05, 2019 Sep 30 Zimmer Biomet Holdings, Inc. (NYSE:ZBH) completed the acquisition of remaining 41.18% stake in MedTech Société Anonyme from Bertin Nahum, Bpifrance Investissement and other shareholders.
Zimmer Biomet Holdings, Inc. Does Not Provide Updated Financial Guidance for 2020 Sep 12 Shareholder Returns Z1BH34 BR Medical Equipment BR Market 7D 0% -0.4% -1.1% 1Y n/a 5.9% -14.9%
See full shareholder returns
Return vs Market: Insufficient data to determine how Z1BH34 performed against the BR Market .
Price Volatility Is Z1BH34's price volatile compared to industry and market? Z1BH34 volatility Z1BH34 Average Weekly Movement n/a Medical Equipment Industry Average Movement 6.8% Market Average Movement 5.1% 10% most volatile stocks in BR Market 9.7% 10% least volatile stocks in BR Market 3.0%
Stable Share Price: Z1BH34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine Z1BH34's volatility change over the past year.
About the Company Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products.
Show more Zimmer Biomet Holdings, Inc. Fundamentals Summary How do Zimmer Biomet Holdings's earnings and revenue compare to its market cap? Z1BH34 fundamental statistics Market cap R$129.62b Earnings (TTM ) R$6.69b Revenue (TTM ) R$46.93b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) Z1BH34 income statement (TTM ) Revenue US$7.60b Cost of Revenue US$2.13b Gross Profit US$5.46b Other Expenses US$4.38b Earnings US$1.08b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 5.44 Gross Margin 71.90% Net Profit Margin 14.27% Debt/Equity Ratio 53.6%
How did Z1BH34 perform over the long term?
See historical performance and comparison Dividends
0.9% Current Dividend Yield When do you need to buy Z1BH34 by to receive an upcoming dividend? Zimmer Biomet Holdings dividend dates Ex Dividend Date Dec 27 2024 Dividend Pay Date Feb 06 2025 Days until Ex dividend 5 days Days until Dividend pay date 36 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/31 23:32 End of Day Share Price 2024/10/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Zimmer Biomet Holdings, Inc. is covered by 62 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Toung Argus Research Company Stephan Gasteyger Atlantic Equities LLP Jeffrey Johnson Baird
Show 59 more analysts 
